MarketPeel
Insider Trading Intelligence
Pricing
…
WF

William P. Forbes

HRTX
EVP, CHIEF DEVELOPMENT OFFICER · HERON THERAPEUTICS, INC. /DE/ · CIK 0001314760
FILING MIX · LIFETIME62%/38%
BUYS
48
SELLS
29
TOTAL VALUE
$139.9K
COMPANIES
3
ACTIVE SINCE
Feb 2021
HOLDINGS NOW
270,861
AVG SELL PX
—
TRADE KIND
SHOWING 77 / 77
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by William P. Forbes, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+50.00%+17.29%+0.87%+16.42%+12.01%—
14d4+75.00%+12.27%+2.23%+10.03%+9.22%—
30d4+50.00%+35.65%+4.36%+31.29%+22.87%—
60d4+50.00%+50.65%+4.88%+45.77%+36.94%—
90d4+50.00%+80.34%+10.98%+69.36%+65.75%—
180d4+50.00%+66.69%+13.79%+52.90%+44.97%—
1y4+50.00%-27.87%+31.45%-59.32%-63.18%—
2y4+50.00%-42.83%+48.05%-90.88%-93.48%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
HRTX · 221,611 shares · as of Jun 6, 2026
093,555187,110280,665374,220202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 48 buys / 29 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
12,500——221,611Jun 6, 2026Jun 8, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
12,500——12,500Jun 6, 2026Jun 8, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,770——209,111Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,694——128,638Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,770——176,545Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,694——197,341Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——185,647Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——27,120Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,695——181,773Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,695——140,332Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
188,315——188,315Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
188,314——188,314Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,875——30,994Jan 19, 2026Jan 20, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,875——170,078Jan 19, 2026Jan 20, 2026 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
400——400Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
3,750——3,750Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
2,000——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
1,500——1,500Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
2,250——2,250Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
400——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,500——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
2,000——2,000Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
2,250——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
1,250——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
SALE
3,750——0Nov 4, 2025Nov 6, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
1,250——1,250Nov 4, 2025Nov 6, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,694——152,027Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,694——166,203Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——154,509Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——34,869Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,695——163,721Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,695——150,635Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——38,743Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——138,940Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
12,500——135,066Jun 6, 2025Jun 9, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
12,500——25,000Jun 6, 2025Jun 9, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
11,694——175,416Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
11,694——122,566Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,875——42,617Apr 19, 2025Apr 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,875——110,872Apr 19, 2025Apr 22, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
75,000——75,000Mar 26, 2025Mar 28, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
374,220——374,220Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
187,110——187,110Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——106,997Jan 19, 2025Jan 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——46,492Jan 19, 2025Jan 22, 2025 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
30,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
40,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
25,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
8,000——8,000Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
8,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
SALE
45,000——0Nov 22, 2024Nov 26, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Nov 22, 2024Nov 26, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——103,123Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——50,366Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,875——54,240Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,875——99,249Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
12,500——37,500Jun 6, 2024Jun 7, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
12,500——95,374Jun 6, 2024Jun 7, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
3,874——82,874Apr 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Development Officer
3,874——58,115Apr 19, 2024Apr 19, 2024 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Mar 20, 2024Mar 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
61,989——61,989Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
371,935——371,935Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
25,000$1.09$27.3K79,000Nov 17, 2023Nov 21, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Development Officer
50,000$0.94$47.0K54,000Nov 16, 2023Nov 20, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASE
5,000$6.67$33.4K14,855Mar 31, 2023Apr 3, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Mar 29, 2023Mar 31, 2023 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASE
5,000$6.46$32.3K9,855Mar 17, 2023Mar 20, 2023 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
48,000——48,000Jun 29, 2022Jun 29, 2022 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Mar 3, 2022Mar 7, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
137,500——137,500Feb 11, 2022Jul 1, 2022 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
137,500——137,500Feb 11, 2022Feb 15, 2022 ↗View →
XAIR
BEYOND AIR, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Mar 4, 2021Mar 8, 2021 ↗View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000——200,000Feb 1, 2021Feb 3, 2021 ↗View →
Other insiders · HRTX
Loading peer insiders…
About this filer
CIK 0001314760
ROLE
EVP, Chief Development Officer
PRIMARY
HRTX
COMPANIES
3
ACTIVE SINCE
Feb 2021
MARKETPEEL · /INSIDER/0001314760DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback